A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has collaborations with Adimab LLC; Turbine Ltd.; Harvard University; Sibylla Biotech; and Congruence Therapeutics. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
Financial Summary
| Share Statistics | OPHLY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7,029.9 | $579.1 | 72% |
|
| Shares Out (Mil) | 3.0 | 43.0 | 10% |
|
| Institutional Ownership | 49.9% | 84.3% | 27% |
|
| Float (Mil) | 389.4 | 46.8 | 83% |
|
| Beta | 0.14 | 0.62 | 10% |
|
| Avg Daily Volume (000s) | 36 | 285 | 25% |
|
| Price Change (52-week) |
36.3% | 63.8% | 73% |
|
| Growth | OPHLY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 3.0% | 6.7% | 27% |
|
| Net Income (5yr) | (8.4%) | (1.4%) | 30% |
|
| EPS (5yr) | (7.3%) | 14.9% | 23 |
|
| Dividends (5yr) | 2.2% | 0.0% | 69% |
|
| Cash Flow (5yr) | 44.7% | (14.9%) | 92% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | OPHLY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3,244 | $272 | 68% |
|
| Net Income (TTM) (Mil) | $439 | ($11) | 77% |
|
| EPS (TTM) | $0.934 | ($0.500) | 60% |
|
| Operating Cash Flow (TTM) (Mil) | $861 | ($6) | 79% |
|
| Net Cash Flow (TTM) (Mil) | $1,117 | $4 | 95% |
|
| Long-Term Debt (Q1) (Mil) | $519 | $7 | 59% |
|
| Enterprise Value (Q1) (Mil) | $6,569 | $522 | 67% |
|
| Valuation | OPHLY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.73 | na |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | OPHLY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 72.5% | 65.9% | 83% |
|
| Net Margin | 13.5% | 0.7% | 70% |
|
| ROA | 6.8% | (24.6%) | 79% |
|
| ROE | 8.3% | (19.7%) | 52% |
|
| Liabilities to Assets | 22.6% | 35.5% | 15% |
|
| F-Score | na | 3 | na |
|
Ono Pharmaceutical Co., Ltd. did not pass any screens on 7/31/2026.
